Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.
Identifieur interne : 001676 ( Main/Exploration ); précédent : 001675; suivant : 001677Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.
Auteurs : Xufang Deng [États-Unis] ; Sarah E. Stjohn [États-Unis] ; Heather L. Osswald [États-Unis] ; Amornrat O'Brien [États-Unis] ; Bridget S. Banach [États-Unis] ; Katrina Sleeman [États-Unis] ; Arun K. Ghosh [États-Unis] ; Andrew D. Mesecar [États-Unis] ; Susan C. Baker [États-Unis]Source :
- Journal of virology [ 1098-5514 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- génétique : Coronavirus.
- pharmacologie : Inhibiteurs de protéases.
- physiologie : Coronavirus.
- Animaux, Coronavirus, Cricetinae, Humains, Lignée cellulaire, Lignée cellulaire tumorale, Réplication virale, Résistance virale aux médicaments, Souris, Souris de lignée C57BL.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Protease Inhibitors.
- drug effects : Coronavirus.
- genetics : Coronavirus.
- physiology : Coronavirus.
- Animals, Cell Line, Cell Line, Tumor, Cricetinae, Drug Resistance, Viral, Humans, Mice, Mice, Inbred C57BL, Virus Replication.
Abstract
Viral protease inhibitors are remarkably effective at blocking the replication of viruses such as human immunodeficiency virus and hepatitis C virus, but they inevitably lead to the selection of inhibitor-resistant mutants, which may contribute to ongoing disease. Protease inhibitors blocking the replication of coronavirus (CoV), including the causative agents of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), provide a promising foundation for the development of anticoronaviral therapeutics. However, the selection and consequences of inhibitor-resistant CoVs are unknown. In this study, we exploited the model coronavirus, mouse hepatitis virus (MHV), to investigate the genotype and phenotype of MHV quasispecies selected for resistance to a broad-spectrum CoV 3C-like protease (3CLpro) inhibitor. Clonal sequencing identified single or double mutations within the 3CLpro coding sequence of inhibitor-resistant virus. Using reverse genetics to generate isogenic viruses with mutant 3CLpros, we found that viruses encoding double-mutant 3CLpros are fully resistant to the inhibitor and exhibit a significant delay in proteolytic processing of the viral replicase polyprotein. The inhibitor-resistant viruses also exhibited postponed and reduced production of infectious virus particles. Biochemical analysis verified double-mutant 3CLpro enzyme as impaired for protease activity and exhibiting reduced sensitivity to the inhibitor and revealed a delayed kinetics of inhibitor hydrolysis and activity restoration. Furthermore, the inhibitor-resistant virus was shown to be highly attenuated in mice. Our study provides the first insight into the pathogenicity and mechanism of 3CLpro inhibitor-resistant CoV mutants, revealing a low genetic barrier but high fitness cost of resistance. Importance: RNA viruses are infamous for their ability to evolve in response to selective pressure, such as the presence of antiviral drugs. For coronaviruses such as the causative agent of Middle East respiratory syndrome (MERS), protease inhibitors have been developed and shown to block virus replication, but the consequences of selection of inhibitor-resistant mutants have not been studied. Here, we report the low genetic barrier and relatively high deleterious consequences of CoV resistance to a 3CLpro protease inhibitor in a coronavirus model system, mouse hepatitis virus (MHV). We found that although mutations that confer resistance arise quickly, the resistant viruses replicate slowly and do not cause lethal disease in mice. Overall, our study provides the first analysis of the low barrier but high cost of resistance to a CoV 3CLpro inhibitor, which will facilitate the further development of protease inhibitors as anti-coronavirus therapeutics.
DOI: 10.1128/JVI.01528-14
PubMed: 25100843
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F50
- to stream PubMed, to step Curation: 000F50
- to stream PubMed, to step Checkpoint: 001023
- to stream Ncbi, to step Merge: 002937
- to stream Ncbi, to step Curation: 002937
- to stream Ncbi, to step Checkpoint: 002937
- to stream Main, to step Merge: 001682
- to stream Main, to step Curation: 001676
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.</title>
<author><name sortKey="Deng, Xufang" sort="Deng, Xufang" uniqKey="Deng X" first="Xufang" last="Deng">Xufang Deng</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stjohn, Sarah E" sort="Stjohn, Sarah E" uniqKey="Stjohn S" first="Sarah E" last="Stjohn">Sarah E. Stjohn</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Osswald, Heather L" sort="Osswald, Heather L" uniqKey="Osswald H" first="Heather L" last="Osswald">Heather L. Osswald</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Brien, Amornrat" sort="O Brien, Amornrat" uniqKey="O Brien A" first="Amornrat" last="O'Brien">Amornrat O'Brien</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Banach, Bridget S" sort="Banach, Bridget S" uniqKey="Banach B" first="Bridget S" last="Banach">Bridget S. Banach</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K" last="Ghosh">Arun K. Ghosh</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D" last="Mesecar">Andrew D. Mesecar</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA sbaker1@luc.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25100843</idno>
<idno type="pmid">25100843</idno>
<idno type="doi">10.1128/JVI.01528-14</idno>
<idno type="wicri:Area/PubMed/Corpus">000F50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F50</idno>
<idno type="wicri:Area/PubMed/Curation">000F50</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001023</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001023</idno>
<idno type="wicri:Area/Ncbi/Merge">002937</idno>
<idno type="wicri:Area/Ncbi/Curation">002937</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002937</idno>
<idno type="wicri:Area/Main/Merge">001682</idno>
<idno type="wicri:Area/Main/Curation">001676</idno>
<idno type="wicri:Area/Main/Exploration">001676</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.</title>
<author><name sortKey="Deng, Xufang" sort="Deng, Xufang" uniqKey="Deng X" first="Xufang" last="Deng">Xufang Deng</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stjohn, Sarah E" sort="Stjohn, Sarah E" uniqKey="Stjohn S" first="Sarah E" last="Stjohn">Sarah E. Stjohn</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Osswald, Heather L" sort="Osswald, Heather L" uniqKey="Osswald H" first="Heather L" last="Osswald">Heather L. Osswald</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Brien, Amornrat" sort="O Brien, Amornrat" uniqKey="O Brien A" first="Amornrat" last="O'Brien">Amornrat O'Brien</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Banach, Bridget S" sort="Banach, Bridget S" uniqKey="Banach B" first="Bridget S" last="Banach">Bridget S. Banach</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K" last="Ghosh">Arun K. Ghosh</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D" last="Mesecar">Andrew D. Mesecar</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA sbaker1@luc.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Coronavirus (drug effects)</term>
<term>Coronavirus (genetics)</term>
<term>Coronavirus (physiology)</term>
<term>Cricetinae</term>
<term>Drug Resistance, Viral</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus ()</term>
<term>Coronavirus (génétique)</term>
<term>Coronavirus (physiologie)</term>
<term>Cricetinae</term>
<term>Humains</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Lignée cellulaire</term>
<term>Lignée cellulaire tumorale</term>
<term>Réplication virale</term>
<term>Résistance virale aux médicaments</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Cricetinae</term>
<term>Drug Resistance, Viral</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus</term>
<term>Cricetinae</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Lignée cellulaire tumorale</term>
<term>Réplication virale</term>
<term>Résistance virale aux médicaments</term>
<term>Souris</term>
<term>Souris de lignée C57BL</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Viral protease inhibitors are remarkably effective at blocking the replication of viruses such as human immunodeficiency virus and hepatitis C virus, but they inevitably lead to the selection of inhibitor-resistant mutants, which may contribute to ongoing disease. Protease inhibitors blocking the replication of coronavirus (CoV), including the causative agents of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), provide a promising foundation for the development of anticoronaviral therapeutics. However, the selection and consequences of inhibitor-resistant CoVs are unknown. In this study, we exploited the model coronavirus, mouse hepatitis virus (MHV), to investigate the genotype and phenotype of MHV quasispecies selected for resistance to a broad-spectrum CoV 3C-like protease (3CLpro) inhibitor. Clonal sequencing identified single or double mutations within the 3CLpro coding sequence of inhibitor-resistant virus. Using reverse genetics to generate isogenic viruses with mutant 3CLpros, we found that viruses encoding double-mutant 3CLpros are fully resistant to the inhibitor and exhibit a significant delay in proteolytic processing of the viral replicase polyprotein. The inhibitor-resistant viruses also exhibited postponed and reduced production of infectious virus particles. Biochemical analysis verified double-mutant 3CLpro enzyme as impaired for protease activity and exhibiting reduced sensitivity to the inhibitor and revealed a delayed kinetics of inhibitor hydrolysis and activity restoration. Furthermore, the inhibitor-resistant virus was shown to be highly attenuated in mice. Our study provides the first insight into the pathogenicity and mechanism of 3CLpro inhibitor-resistant CoV mutants, revealing a low genetic barrier but high fitness cost of resistance. Importance: RNA viruses are infamous for their ability to evolve in response to selective pressure, such as the presence of antiviral drugs. For coronaviruses such as the causative agent of Middle East respiratory syndrome (MERS), protease inhibitors have been developed and shown to block virus replication, but the consequences of selection of inhibitor-resistant mutants have not been studied. Here, we report the low genetic barrier and relatively high deleterious consequences of CoV resistance to a 3CLpro protease inhibitor in a coronavirus model system, mouse hepatitis virus (MHV). We found that although mutations that confer resistance arise quickly, the resistant viruses replicate slowly and do not cause lethal disease in mice. Overall, our study provides the first analysis of the low barrier but high cost of resistance to a CoV 3CLpro inhibitor, which will facilitate the further development of protease inhibitors as anti-coronavirus therapeutics.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Illinois</li>
<li>Indiana</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Illinois"><name sortKey="Deng, Xufang" sort="Deng, Xufang" uniqKey="Deng X" first="Xufang" last="Deng">Xufang Deng</name>
</region>
<name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name>
<name sortKey="Banach, Bridget S" sort="Banach, Bridget S" uniqKey="Banach B" first="Bridget S" last="Banach">Bridget S. Banach</name>
<name sortKey="Ghosh, Arun K" sort="Ghosh, Arun K" uniqKey="Ghosh A" first="Arun K" last="Ghosh">Arun K. Ghosh</name>
<name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D" last="Mesecar">Andrew D. Mesecar</name>
<name sortKey="O Brien, Amornrat" sort="O Brien, Amornrat" uniqKey="O Brien A" first="Amornrat" last="O'Brien">Amornrat O'Brien</name>
<name sortKey="Osswald, Heather L" sort="Osswald, Heather L" uniqKey="Osswald H" first="Heather L" last="Osswald">Heather L. Osswald</name>
<name sortKey="Sleeman, Katrina" sort="Sleeman, Katrina" uniqKey="Sleeman K" first="Katrina" last="Sleeman">Katrina Sleeman</name>
<name sortKey="Stjohn, Sarah E" sort="Stjohn, Sarah E" uniqKey="Stjohn S" first="Sarah E" last="Stjohn">Sarah E. Stjohn</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001676 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001676 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:25100843 |texte= Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25100843" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |